

*For immediate Release*

Melbourne, Australia — 26 July 2007

## **\$11.1 million in Quarterly Royalties from Relenza**

Biota Holdings (ASX:BTA) today announced that it had received written notification from GlaxoSmithKline (GSK) that indicative royalties for Relenza were \$11.1m during the three months ended 30 June 2007, bringing the full year Relenza royalties to \$39.8m compared to \$5.2m in 2006.

Biota CEO, Peter Cook commented, *"This is another strong quarterly result confirming the ongoing global demand for Relenza for government stockpiling. Despite clearance of a backlog of orders during the third quarter, the fourth quarter figures imply a continuing overall trend of an increase in production capacity"*.

Indicative royalties advised by GSK by quarter and the implied number of courses sold by quarter is set out below:

	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>
Indicative royalties \$m	5.4	7.3	16.0	11.1
Indicative sales \$m	72.3	89.1	220.8	158.2
Implied number of courses per quarter (m)	2.6	3.2	8.0	5.7
Implied annualised number of courses (m)	10.4	12.8	32.0	22.8

## **Full Year Profit**

Biota previously advised that its profit before tax for the year would be at least \$18 million, based on the fourth quarter royalties being substantially in line with those of the third quarter (ASX release dated 31 May 2007). Now that the June quarter royalties have been advised by GSK, Biota expects profit before tax to exceed \$17 million.

## **About Biota**

Biota is a leading antiviral drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.

Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has key partnerships with Daiichi-Sankyo for the development of second generation influenza antivirals and with Inverness Medical to market Biota developed FLU OIA influenza diagnostics.

Relenza™ is a registered trademark of the GlaxoSmithKline group of companies.

BioStar® OIA® FLU and BioStar® OIA® FLU A/B are registered trademarks of Inverness Medical.

*\*Further information available at [www.biota.com.au](http://www.biota.com.au).*

### **Investor / Analyst Enquiries**

#### **Biota Holdings Limited**

Peter Cook

T: +61 3 9915 3720

Damian Lismore

T: +61 3 9915 3721

### **Media Enquiries**

Tim Duncan or Nerida Mossop

Hinton & Associates

T: +61 3 9600 1979

M: +61 408 441 122